Leeds, UK – 22 October 2020, – 4D pharma plc (AIM: DDDD) (“4D” or the “Company”), a pharmaceutical company leading the development of Live Biotherapeutic Products (“LBPs”), and Longevity Acquisition
Open Orphan/hVIVO Signs Contract with UK Government for the Development of a COVID-19 Human Challenge Study Model
Phase II Dose Confirmed and Encouraging Survival Data
Midatech has today announced encouraging headline results from a Phase I study at the University of California, San Francisco (‘UCSF’) in patients with the orphan condition, Diffuse Intrinsic Pontine Glioma
Further to our announcement of 24 September 2020 and further media comment the Company confirms that it remains in advanced negotiations with the UK Government and other partners for a
4D pharma announces three presentations at The Society for Immunotherapy of Cancer (SITC) Annual Meeting 2020
Positive trends seen in primary efficacy endpoint of the study of overall response in both IBS-C and IBS-D subgroups
Cathal Friel, Executive Chairman, Open Orphan, said: This is very exciting news as we are now signing up such challenge study contracts on a regular basis .
Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials notes
Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is
In a bid to help to bring drugs to market for patients most in need, Elsevier, a global research publishing and information analytics provider.
